Chandan Healthcare Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 25 Aug 2026 | Healthcare Services | Market Cap: ₹606 Cr
Chandan Healthcare Limited expects top-line growth much higher than 30% in the next financial year (FY’27), surpassing current projections. The company expects revenue growth significantly higher than 30% in FY'27, surpassing previous projections.
From Chandan Healthcare Ltd's Q3 FY26 earnings-call transcript · updated 25 Aug 2026.
Price
₹222
Market Cap
₹606 Cr
P/E Ratio
23.1
How does Chandan Healthcare Ltd rank in Healthcare Services?
Compare Chandan Healthcare Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Chandan Healthcare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹65 Cr, net profit ₹5 Cr.
Full financials →📊 Revenue & Sales Performance
- →Chandan Healthcare Limited expects top-line growth much higher than 30% in the next financial year (FY’27), surpassing current projections.
- →New government contracts, including a INR55 crore per year project in Punjab and Guwahati, will act as significant growth drivers.
- →Expansion plans include launching 18 new labs and 37 comprehensive centers in the current year, with further scale-up in the next two to three years.
- →The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion.
- →A strategic focus on Tier 2, 3, and 4 cities, which contribute 90% of the business, will support volume growth.
- →Growth is supported by a robust team and preferential shares funding of INR104 crores, ensuring smooth expansion.
- →Quarterly incremental growth is expected, with visible improvements in Q4 FY’27 and beyond.
📈 Profitability & Margins
- →The company expects revenue growth significantly higher than 30% in FY'27, surpassing previous projections.
- →Expansion plans include government contracts worth INR55-52 crores annually (Punjab and Guwahati project), acting as a game changer.
- →EBITDA margins are anticipated to improve quarter-on-quarter, with current diagnostic EBITDA margins already above 30%; aiming to increase overall margins to 35%+.
- →EBITDA margins for B2C business are around 35-40%, considered sustainable, though consolidated margins average 30-35% due to B2B and B2G segments.
- →Positive net cash inflow from operations is expected with improving working capital.
- →No further equity dilution is anticipated for capex over the next 2-3 years due to preferential shares funds already raised.
- →PAT and bottom line are expected to reflect significant growth aligned with revenue and contract wins starting next year.
🏗️ Capital Expenditure Plans
- →Planned investment of INR 100 crores over the next three years for setting up 100 new laboratories.
- →Each laboratory requires approximately INR 1 crore in capex (INR 50-75 lakhs for setup plus INR 50 lakhs for machines).
- →Preferential shares of INR 104 crores have been raised, with INR 26 crores already received, to fund expansion smoothly.
- →Expansion plan includes launching 13 new labs, 3 comprehensive centres, a PET scan facility at Gorakhpur, and a genome lab at Lucknow in the coming year.
- →Central lab and wellness centre to begin in H1 FY27 at Jankipuram, Lucknow, expected to be the largest lab in Uttar Pradesh.
- →The company is focusing on both owned labs (capex-heavy) and franchisee collection points (minimal capex).
- →Expansion involves not only metropolitan cities but also Tier 2, 3, and 4 cities across 13 states.
💰 Fundraising & Capital Structure
- →Chandan Healthcare Limited has already raised funds through preferential shares amounting to INR104 crores.
- →As of now, INR26 crores (25% of the preferential shares) has been received, with the balance expected within the next year.
- →This fundraising is considered sufficient for the company's expansion plans over the next year.
- →Management does not anticipate any further equity dilution or fundraising through equity for the next two to three years.
- →There is no mention of any planned or ongoing debt fundraising in the provided content.
- →Overall, the company is well-capitalized for near-term expansion and does not foresee additional fundraising needs imminently.
📋 Order Book & Pipeline
Key Metrics
Continue your research
What Chandan Healthca's management said in earlier quarters
Others in Healthcare Services this season
- Vijaya Diagnostic Centre Ltd (Q3 FY26)
FY '27 capex of INR 100-120 crores planned, supporting network expansion (Page 5). Key concall takeaways from Vijaya Diagnost.'s Q3 FY26 earnings call — and…
- Aster DM Quality (Q3 FY26)
Mature hospitals show steady revenue growth of 14%, hospitals 3-7 years old growing at 10%, and new assets under 3 years growing at 19%. Key concall takeaways…
- Rainbow Childrens Medicare Ltd (Q3 FY26)
Revenue growth for the quarter was 12% YoY; 9% for the first 9 months of the financial year. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
- Krishna Institu. (Q3 FY26)
Hospitals like Kondapur to see 20-25% year-on-year growth post new facility commissioning (Pg.18). Key concall takeaways from Krishna Institute of Medical…
Frequently Asked Questions
What were Chandan Healthcare Ltd Q3 FY26 results?
Chandan Healthcare Limited expects top-line growth much higher than 30% in the next financial year (FY’27), surpassing current projections. The company expects revenue growth significantly higher than 30% in FY'27, surpassing previous projections.
What is Chandan Healthcare Ltd share price analysis?
Chandan Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 23.1 with a market cap of ₹606 Cr. Investors should review the full earnings analysis for detailed insights.
Is Chandan Healthcare Ltd planning capital expenditure?
Planned investment of INR 100 crores over the next three years for setting up 100 new laboratories.
Keep Chandan Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.